Week in Review: China Life Science Deals Total $550 Million

Deals and Financings Pfizer acquired China/Asia rights for Cresemba ® , an antifungal drug developed by Swiss pharma Basilea, in a $226 million deal; Everest Medicines, a China startup backed by C-Bridge, formed a $224 million partnership with San Diego 's Arena Pharma to develop two Arena small molecule candidates in China/Asia; Genova Biotech of Changzhou raised $50 million in a funding led by Tasly Pharma to develop state-of-the-art diabetes products for China ; Etong Healthcare of Shanghai , a company offering health exams, announced a $30 Million Series B funding, led by Vision Plus Capital of Hangzhou; MicuRx Pharma, a San Francisco-Shanghai company, closed a $15 million financing to complete a China Phase III trial of its oral antibiotic for MRSA; Shenzhen BioScien in-licensed China rights to an immunotherapeutic vaccine for prostate cancer from Generex of the US in a deal worth $5 million; Esaote, an Italian medical imaging company, was acquired by a group of China investors that included Alibaba and China medical device companies; Shenzhen's BGI Genomics formed a partnership with California 's Sanguine BioSciences, a company that links patients with clinical trials; Company News WuXi Biologics completed construction of its $150 million 30,000 liter contract biomanufacturing facility in China ; Johnson & Johnson Innovation will open a JLABS life science incubator in Shanghai 's Zhangjiang Hi-Tech Park, with space for 50 startup companies;   Trials and Approvals   Bristol-Myers Squibb put an early stop to its China Phase III trial of PD-1 inhibitor Opdivo because of positive results; Xynomic Pharma, a China-US oncology pharma, will start a Phase I/II trial of its novel HDAC inhibitor Abexinostat, in combination with Janssen 's Imbruvica ® , a first-in-class BTK inhibitor; BeyondSpring announced that China awarded "National Science and Technology Major Project" designation to Plinabulin, a cancer and neutropenia treatment. Stock Symbols: (NYSE: PFE) (SIX: BSLN) (NSDQ: ARNA) (NYSE: BABA) (OTCQB: GNBT) (SHZ: 300676) (HK: 2269) (NYSE: JNJ) (NYSE: BMY) (NSDQ: BYSI) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.